Free Trial
→ Satellite Images Spot Potential $10 Trillion Discovery (From Altimetry) (Ad)tc pixel
NASDAQ:MGTX

MeiraGTx Q1 2024 Earnings Report

MeiraGTx logo
$9.90 +0.15 (+1.54%)
Closing price 04:00 PM Eastern
Extended Trading
$9.70 -0.20 (-1.97%)
As of 04:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

MeiraGTx EPS Results

Actual EPS
-$0.77
Consensus EPS
-$0.32
Beat/Miss
Missed by -$0.45
One Year Ago EPS
N/A

MeiraGTx Revenue Results

Actual Revenue
$0.70 million
Expected Revenue
$16.38 million
Beat/Miss
Missed by -$15.68 million
YoY Revenue Growth
N/A

MeiraGTx Announcement Details

Quarter
Q1 2024
Date
5/9/2024
Time
N/A
Conference Call Date
Thursday, May 9, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

MeiraGTx's Q1 2026 earnings is estimated for Tuesday, May 12, 2026, based on past reporting schedules, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Q1 2026 Earnings Report

Conference Call Resources

Powered by Quartr

Earnings Documents

MeiraGTx's Q1 2024 Press ReleasePress Release
(8-K)
MeiraGTx's Q1 2024 Quarterly reportQuarterly report
(10-Q)

MeiraGTx Earnings Headlines

Evercore Maintains Positive Stance on MeiraGTx Holdings plc (MGTX) Amid Sector Revisions
April 18, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/evercore-maintains-positive-stance-meiragtx-135856262.html
Eli Lilly partner MeiraGTx regains rights for genetic eye disease drug from Johnson & Johnson
April 16, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/eli-lilly-partner-meiragtx-regains-rights-for-genetic-eye-disease-drug-from-johnson-johnson/ar-AA213r8g
I was right about SpaceX
Jeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.tc pixel
May 6 at 1:00 AM  |  Brownstone Research (Ad)
MeiraGTx eyes $100M equity offering after gene therapy deal with J&J
April 16, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/meiragtx-eyes-100m-equity-offering-after-gene-therapy-deal-with-j-j/ar-AA212KsP
MeiraGTx Holdings plc (MGTX) Discusses 3-Year Phase I Data on AAV-hAQP1 for Radiation-Induced Xerostomia and Commercial Opportunity Transcript
April 16, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4891311-meiragtx-holdings-plc-mgtx-discusses-3-year-phase-i-data-on-aav-haqp1-for-radiation-induced
MeiraGTx Holdings plc (MGTX) Discusses 3-Year Phase I Data on AAV-hAQP1 for Radiation-Induced Xerostomia and Commercial Opportunity - Slideshow
April 16, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4891379-meiragtx-holdings-plc-mgtx-discusses-3-year-phase-i-data-on-aav-haqp1-for-radiation-induced
See More MeiraGTx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MeiraGTx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MeiraGTx and other key companies, straight to your email.

About MeiraGTx

MeiraGTx (NASDAQ:MGTX) is a clinical-stage biotechnology company dedicated to developing gene therapies for the treatment of rare diseases. Founded in 2014 as an outgrowth of research at University College London, the company focuses on leveraging adeno-associated virus (AAV) vectors to deliver functional genes to target tissues. MeiraGTx’s pipeline spans ocular, central nervous system and systemic indications, addressing conditions such as inherited retinal dystrophies and neurodegenerative disorders that currently lack effective therapies.

The company’s lead programs include AAV-based candidates designed to restore or replace defective genes underlying rare retinal diseases and to modulate cellular pathways in neurological disorders. MeiraGTx has established an end-to-end platform encompassing vector design, process development, and manufacturing scale-up, with capabilities housed in facilities across the United Kingdom and the United States. This integrated approach aims to accelerate the transition from preclinical research to clinical trials and, ultimately, patient access.

MeiraGTx completed its initial public offering on the Nasdaq in April 2018 and operates research laboratories in London alongside a manufacturing and clinical operations center in the New York metropolitan area. The company’s leadership team comprises industry veterans with extensive experience in gene therapy development, regulatory affairs and commercialization. MeiraGTx continues to advance its clinical programs in collaboration with academic institutions and contract research organizations, targeting global patient populations in need of novel therapeutic options.

View MeiraGTx Profile
Earnings Tools